HIF-1α Inhibitor Compounds for Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticancer agents face challenges in effectively targeting and inhibiting HIF-1α, a key transcription factor involved in cancer progression and adaptation to hypoxia, which contributes to cancer cell resistance and poor prognosis.
Innovation Solution
Development of novel compounds, such as those represented by Formula I, which inhibit HIF-1α activity and angiogenesis, offering potential therapeutic benefits for cancer, diabetic retinopathy, and rheumatoid arthritis by selectively targeting HIF-1α-mediated gene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anticancer agents are used to target HIF-1α, then cancer cell growth may be inhibited, but the agents fail to effectively suppress HIF-1α activity due to its role in hypoxia adaptation and resistance mechanisms
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of HIF-1α inhibitors through systematic variations in molecular composition (e.g., different substituents R1-R6, ring structures, and side chains). This allows optimization of the inhibitors' ability to bind to and suppress HIF-1α activity, thereby improving inhibition efficacy while overcoming resistance mechanisms that conventional agents cannot address effectively.
2Measurement precision
If HIF-1α inhibitors are developed to selectively target HIF-1α-mediated gene expression, then specific down-regulation of target genes like VEGFA and EPO is achieved, but the complexity of achieving selective inhibition without affecting other pathways increases
Solution Approach 1:
The patent applies local quality by designing HIF-1α inhibitors with specific localized functional groups and structural features (e.g., particular substituent patterns at R1-R6 positions, specific ring configurations) that enable selective binding to HIF-1α. This localized structural optimization allows the compounds to specifically down-regulate HIF-1α target genes like VEGFA and EPO while minimizing interference with other cellular pathways, thereby achieving high selectivity.
3Reliability
If novel compounds are designed to inhibit HIF-1α activity and angiogenesis, then therapeutic benefits for cancer and related conditions are enhanced, but the manufacturing process and structural complexity of the compounds increase
Solution Approach 1:
The patent employs segmentation by dividing the complex HIF-1α inhibitor molecules into modular structural components (core ring structures with variable substituents R1-R6, different side chains, and functional groups). This modular approach allows for systematic synthesis where individual components can be prepared separately and assembled, thereby improving ease of manufacture while maintaining the therapeutic effectiveness needed for inhibiting HIF-1α activity and angiogenesis.
Data Source
AI summary
The present invention relates to novel compounds as HIF-1α inhibitors, manufacturing process thereof, and a pharmaceutical compositions. The compounds according to the present invention having inhibition activity against HIF-1α, can be used as a therapeutic prevention and/or treatment for various solid cancers such as colon cancer, liver cancer, stomach cancer and breast cancer. Also, the compounds according to the present invention are useful in the treatment of diabetic retinopathy and rheumatoid arthritis, which are aggravated by HIF-1α-mediated VEGFA expression.